Vliyanie na prognoz estrogenovykh retseptorov a v opukholevykh kletkakh u patsientov, radikal'no operirovannykh po povodu nemelkokletochnogo raka legkogo

封面

如何引用文章

全文:

详细

Aim. Evaluation of prognostic role of estrogen receptors a (ERa) expression level at patients with non-small cell lung cancer (NSLC) after surgical treatment. Methods and materials. 115 clinical cases of patients who underwent treatment in N.N.Blokhin Russian Cancer Research Center fr om 2009 to 2016 were studied. There were 95 males and 20 females. All patients had NSLC confirmed by histological analysis and followed-up for long term results. Results. There was no statistical evidence that the level of estrogen a expression in tumor cells has an impact on relapse free survival among men with both adenocarcinoma and squamous cell carcinoma of the lung. Similar results were obtained for women group. Also, no correlations between overall survival and the level of estrogen a expression were noticed among men and women. Thus ERa can’t be used as a predictor marker for patients with NSLC. Conclusion. The level of ERa expression in tumor cells among male patients does not influence on disease prognosis regardless stage of the disease and tumor morphology and can’t be used as a prognostic factor. The impact of the ERa expression level in tumor cells among female patients on disease prognosis is questionable.

作者简介

D Novikov

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: dima-dima.000@mail.ru
аспирант торакального отд-ния торакоабдоминального отд. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

B Polotskiy

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., вед. науч. сотр. торакального отд-ния торакоабдоминального отд. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

T Bogush

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

д-р биол. наук, проф., вед. науч. сотр., рук. группы молекулярных маркеров опухолей лаб. экспериментальной диагностики и биотерапии опухолей 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

M Davidov

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

д-р мед. наук, зав. торакальным отд-нием торакоабдоминального отд. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

B Ahmedov

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

канд. мед. наук, ст. науч. сотр. торакального отд-ния торакоабдоминального отд. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

L Rotobelskaya

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

науч. сотр. рентгенологического отд-ния группы медицинской кибернетики 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

参考

  1. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Евразийский онкологический журнал. 2017.
  2. Sean Blandin Knight, Phil A. Crosbie, Haval Balata et al. Progress and prospects of early detection in lung cancer. Open Biol 2017; 7 (9): 170070. doi: 10.1098/rsob.170070
  3. Богуш Т.А., Дудко Е.А., Беме А.А. и др. Эстрогеновые рецепторы, антиэстрогены и немелкоклеточный рак легкого (обзор). Биохимия. 2010; 75 (12): 1633-41
  4. Новиков Д.В., Полоцкий Б.Е., Богуш Т.А. и др. ЭРb в опухолевых клетках у мужчин, радикально оперированных по поводу рака легкого, как прогностический фактор и потенциальная мишень антиэстрогеновой терапии. Медицинский алфавит. 2018; 15 (Т-1): 25-31.
  5. Chen X.Q, Zheng L.X, Li Z.Y. Clinicopathological significance of oestrogen receptor expression in non-small cell lung cancer. J Int Med Res 2017; 45 (1): 51-8. doi: 10.1177/0300060516666229
  6. Lund-Iversen M, Scott H, Strøm E.H et al. Expression of Estrogen Receptor-a and Survival in Advanced-stage Non-small Cell Lung Cancer. Anticancer Res 2018; 38 (4): 2261-9.
  7. Jinhua Wang, Yali Xu, Li Li et al. FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer. Cancer Med 2017; 6 (1): 275-87.
  8. Berardi R, Morgese F, Santinelli A et al. Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex. Oncotarget 2016; 7 (50): 82648-57. doi: 10.18632/oncotarget.12244
  9. Li W, Tse L.A, Wang F. Prognostic value of estrogen receptors mRNA expression in non-small cell lung cancer: A systematic review and meta-analysis. Steroids 2015; 104:1 29-36.
  10. Li-Han Hsu, Nei-Min Chu, Shu-Huei Kao. Estrogen, Estrogen Receptor and Lung Cancer. Int J Mol Sci 2017; 18 (8): 1713. doi: 10.3390/ijms18081713
  11. Liu C.M, Chiu K.L, Chen T.S et al. Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma. Biomed Research International 2015; 642041. PMID: 25692143. doi: 10.1155/2015/642041
  12. Skjefstad K, Grindstad T, Khanehkenari M.R et al. Prognostic relevance of estrogen receptor alpha, beta and aromatase expression in non-small cell lung cancer. Steroids 2016; 113: 5-13. doi: 10.1016/j.steroids.2016.05.008
  13. Tanaka K, Shimizu K, Kakegawa S et al. Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma. Am J Transl Res 2016; 8: 81-97.
  14. Kadota K, Eguchi T, Villena-Vargas J et al. Nuclear estrogen receptor-b expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration. Oncotarget 2015; 6 (29): 27505-18.
  15. Lund-Iversen M, Scott H, Strøm E.H et al. Expression of Estrogen Receptor-a and Survival in Advanced-stage Non-small Cell Lung Cancer. Anticancer Res 2018; 38 (4): 2261-9.
  16. Pelekanou V, Anastasiou E, Bakogeorgou E et al. Estrogen receptor-alpha isoforms are the main estrogen receptors expressed in non-small cell lung carcinoma. 2018 Feb 15. pii: S0039-128X(18)30016-3. doi: 10.1016/j.steroids.2018.01.008
  17. Rodriguez-Lara V, Ignacio G.S et al. Estrogen induces CXCR4 overexpression and CXCR4/CXL12 pathway activation in lung adenocarcinoma cells in vitro. Endocr Res 2017; 42: 219-31.
  18. Zhao L, Huang S, Mei S et al. Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis. Proc Natl Acad Sci U S A 2018; 115 (16): E3673-E3681. doi: 10.1073/pnas.1803291115
  19. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014.
  20. Wu C.T, Chang Y.L, Shih J.Y, Lee Y.C. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 2005; 130 (4): 979-86.

版权所有 © Consilium Medicum, 2018

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##